<DOC>
	<DOCNO>NCT00003853</DOCNO>
	<brief_summary>RATIONALE : 4'-Iodo-4'-deoxydoxorubicin may improve organ dysfunction ease symptom cause primary systemic amyloidosis . PURPOSE : Phase II trial study effectiveness 4'-iodo-4'-deoxydoxorubicin treating patient primary systemic amyloidosis .</brief_summary>
	<brief_title>4'-Iodo-4'-Deoxydoxorubicin Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate clinical efficacy 4'-iodo-4'-deoxydoxorubicin produce palliation symptom and/or improvement organ dysfunction cause organ infiltration amyloid patient primary systemic amyloidosis . II . Assess safety profile , emphasis cardiac safety , drug patient . III . Evaluate time progression amyloidosis-associated clinical symptom and/or organ dysfunction , duration response , survival patient regimen . OUTLINE : Patients receive 4'-iodo-4'-deoxydoxorubicin IV 1 hour week 4 week . Courses repeat every 12 week . Treatment continue 4 course absence disease progression unacceptable toxicity . Patients follow every 6 month . PROJECTED ACCRUAL : A total 45 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Esorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histochemically proven primary systemic amyloidosis ( AL ) No presence nonAL amyloidosis No amyloidspecific syndrome ( e.g. , skin purpura carpal tunnel syndrome ) evidence disease No vascular amyloid bone marrow biopsy specimen plasmacytoma Must symptomatic organ involvement amyloid ( e.g. , liver , mild cardiac , renal , soft tissue involvement , grade 1 2 peripheral neuropathy ) Demonstrable Mprotein serum/urine OR Clonal population plasma cell bone marrow OR Immunohistochemical stain antilight chain antiserum amyloid fibrils No clinically overt multiple myeloma ( i.e. , monoclonal BMPC great 20 % least one following : bone lesion , anemia , hypercalcemia ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Total bilirubin le 2.0 mg/dL OR Direct bilirubin great 1.0 mg/dL Alkaline phosphatase great 4 time upper limit normal ( ULN ) ALT AST great 3 time ULN Renal : Creatinine clearance great 40 mL/min Cardiovascular : Echocardiographic ejection fraction great 50 % At least 3 year since prior enzyme document myocardial infarction Interventricular septal thickness great 20 mm No New York Heart Association class III IV heart failure No grade 2 3 AV block No chronic atrial fibrillation No sustain ( great 30 second ) ventricular tachycardia frequent episode ( great 20 24 hour ) nonsustained ventricular tachycardia ventricular pair , detect 24hour ambulatory electrocardiographic monitoring Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV positive allow No uncontrolled infection No severe diarrhea controllable medication require total parenteral nutrition No concurrent active malignancy except nonmelanoma skin cancer cervical cancer PRIOR CONCURRENT THERAPY : Biologic therapy : At least 6 week since prior interferon alfa Chemotherapy : No prior anthracyclines great 120 mg/m2 At least 6 week since prior melphalan alkylating agent Endocrine therapy : At least 6 week since prior high dose dexamethasone Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>